newswire, breaking biotechnology and pharma news

Tuesday, June 7, 2011

Biotech/Pharma Stocks News; UV Flu Technologies (OTCBB: UVFT) Receives First Order for the Chinese Marketplace

CENTERVILLE, MA – June 7, 2011 ( Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that it had received its first order of ViraTech UV-400's for test and evaluation for the Chinese marketplace. The units will be manufactured to Chinese electrical standards, and will be shipped for evaluation to 3 hospitals in different Chinese cities.
"This is our first entry into the biggest potential market for our products in the world," said John Lennon, President of UV Flu. "China has approximately 330,000 hospitals, with even greater numbers of clinics, and the spread of airborne bacteria and viruses is epidemic in many areas. Children in many cities are examined before they're allowed on school grounds, and it's not uncommon to see large numbers of people in hospital waiting areas with IVs, providing a fertile environment for the airborne spread of bacteria.
"We have been patiently building our brand over the last several months, and the results are about to be realized. We now have RX-3000s in a significant number of the top hospitals in America, and are currently back-ordered, while a new program we are starting with Hotels later this month is expected to put us in a similar back-order situation on the UV Flu side. We also hope to have our new initiatives in China, along with the Mideast, introduced later this month," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit:
About UV Flu Technologies, Inc. (OTC.BB:UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: For sales:
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
SOURCE: UV Flu Technologies, Inc.
UV Flu Technologies (OTCBB: UVFT) is a showcase biotech stock on (please read disclosure and disclaimers)
Visit the showcase page on

No comments:

Post a Comment